Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder. The company has license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company was incorporated in 2005 and is headquartered in La Jolla, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DARE
Previous Symbol
CUSIPN/A
Phone858-926-7655
Debt
Debt-to-Equity RatioN/A
Current Ratio10.17
Quick Ratio10.17
Price-To-Earnings
Trailing P/E Ratio-0.77
Forward P/E Ratio-0.92
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash Flow$0.6013 per share
Price / Cash1.58
Book Value$2.20 per share
Price / Book0.43
Profitability
EPS (Most Recent Fiscal Year)($1.24)
Net Income$-11,500,000.00
Net MarginsN/A
Return on Equity-58.59%
Return on Assets-55.23%
Miscellaneous
Employees5
Outstanding Shares11,420,000
Market Cap$10.41 million
OptionableNot Optionable
Dare Bioscience (NASDAQ:DARE) Frequently Asked Questions
What is Dare Bioscience's stock symbol?
Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."
How were Dare Bioscience's earnings last quarter?
Dare Bioscience Inc (NASDAQ:DARE) posted its quarterly earnings data on Tuesday, November, 13th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.24) by $0.01. View Dare Bioscience's Earnings History.
When is Dare Bioscience's next earnings date?
What price target have analysts set for DARE?
2 equities research analysts have issued 1 year price targets for Dare Bioscience's stock. Their predictions range from $3.00 to $6.00. On average, they expect Dare Bioscience's share price to reach $4.50 in the next year. This suggests a possible upside of 373.7% from the stock's current price. View Analyst Price Targets for Dare Bioscience.
What is the consensus analysts' recommendation for Dare Bioscience?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dare Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dare Bioscience.
Has Dare Bioscience been receiving favorable news coverage?
News coverage about DARE stock has been trending somewhat positive this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dare Bioscience earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Dare Bioscience's key competitors?
Some companies that are related to Dare Bioscience include SCYNEXIS (SCYX), Addex Therapeutics (ADDXF), X T L Biopharmaceuticals (XTLB), IntelGenx Technologies (IGXT), AzurRx BioPharma (AZRX), KemPharm (KMPH), AEterna Zentaris (AEZS), Celsion (CLSN), Novus Therapeutics (NVUS), VIVUS (VVUS), Heat Biologics (HTBX), GTX (GTXI), Moleculin Biotech (MBRX), Acerus Pharmaceuticals (TRLPF) and ProPhase Labs (PRPH).
Who are Dare Bioscience's key executives?
Dare Bioscience's management team includes the folowing people:
- Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 51)
- Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 59)
- Dr. David Friend, Chief Scientific Officer
- Mr. John Fair, Chief Bus. Officer
- Ms. Mary Jarosz, Global Head of Regulatory Affairs
Who are Dare Bioscience's major shareholders?
Which institutional investors are buying Dare Bioscience stock?
How do I buy shares of Dare Bioscience?
Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dare Bioscience's stock price today?
One share of DARE stock can currently be purchased for approximately $0.95.
How big of a company is Dare Bioscience?
Dare Bioscience has a market capitalization of $10.41 million. The biotechnology company earns $-11,500,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Dare Bioscience employs 5 workers across the globe.
What is Dare Bioscience's official website?
How can I contact Dare Bioscience?
Dare Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]
MarketBeat Community Rating for Dare Bioscience (NASDAQ DARE)
MarketBeat's community ratings are surveys of what our community members think about Dare Bioscience and other stocks. Vote "Outperform" if you believe DARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
